Dominic Buzzacco, MD
Retina Specialist · Dublin, OHNPI 1437394947
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $8,738 of the $11,778 with a category attached, or 74.2%. US Retina LLC accounts for 74.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $4,131 and has fallen 78.6% since, to $883 in 2025.
Across 131 payments — averaging $89.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$9K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$488
- Alimera Sciences, Inc.$328
- Apellis Pharmaceuticals, Inc.$278
- AbbVie$257
- plus $599 from 10 others
What the payments were for
- Food & beverage$3,04026%
- Ownership interest$8,73874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $8,738 |
| Regeneron Healthcare Solutions, Inc. | 34 | $1,090 |
| Genentech USA, Inc. | 25 | $488 |
| Alimera Sciences, Inc. | 18 | $328 |
| Apellis Pharmaceuticals, Inc. | 11 | $278 |
| AbbVie(2 entities) | 12 | $257 |
| Astellas Pharma US Inc | 6 | $181 |
| Eyepoint US, Inc. | 3 | $72 |
| Biogen | 3 | $71 |
| Bausch & Lomb Americas Inc. | 4 | $63 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Sandoz | 1 | $34 |
| Novartis | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Amgen | 1 | $17 |
How this compares
$11,778 in reported general payments places this provider in the 70th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atropine Sulfate | 86 | $2,600 |
| Prednisolone Acetate | 85 | $2,441 |
| Ketorolac Tromethamine | 110 | $1,923 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 117 | $1,090 |
| Brimonidine Tartrate | 27 | $539 |
| ErythromycinErythromycin Base | 36 | $429 |
| Timolol Maleate | 52 | $265 |
| Dorzolamide Hcl | 18 | $250 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $183 |
| Latanoprost | 29 | $162 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Dublin
- Louis ChorichDublin$40K
- Sugat PatelDublin$33K
- Dino KlisovicDublin$21K
- Vishal ParikhDublin$11K
- Johnstone KimDublin$10K
- Joseph ConeyBeachwood$980K
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
- David MillerBeachwood$299K
- Katherine TalcottCleveland$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.